Newly diagnosed glioblastoma (nGBM) remains a major unmet clinical need with limited effective therapeutic options. This phase 1b trial reports safety and preliminary efficacy outcomes of nGBM patients treated with neoantigen-pulsed autologous dendritic cell vaccination.